UBS Group’s Kindred Biosciences, Inc. KIN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2021
Q3
Sell
-64,750
Closed -$593K 9359
2021
Q2
$593K Sell
64,750
-17,935
-22% -$164K ﹤0.01% 3633
2021
Q1
$411K Buy
82,685
+7,149
+9% +$35.5K ﹤0.01% 4073
2020
Q4
$325K Sell
75,536
-8,700
-10% -$37.4K ﹤0.01% 3968
2020
Q3
$361K Sell
84,236
-44,649
-35% -$191K ﹤0.01% 3624
2020
Q2
$579K Buy
128,885
+7,144
+6% +$32.1K ﹤0.01% 3274
2020
Q1
$487K Sell
121,741
-22,338
-16% -$89.4K ﹤0.01% 3228
2019
Q4
$1.22M Buy
144,079
+23,262
+19% +$197K ﹤0.01% 3166
2019
Q3
$827K Buy
120,817
+39,958
+49% +$274K ﹤0.01% 3338
2019
Q2
$674K Buy
80,859
+9,600
+13% +$80K ﹤0.01% 3333
2019
Q1
$653K Sell
71,259
-8,651
-11% -$79.3K ﹤0.01% 3196
2018
Q4
$875K Buy
79,910
+17,764
+29% +$195K ﹤0.01% 3092
2018
Q3
$867K Buy
62,146
+7,572
+14% +$106K ﹤0.01% 3257
2018
Q2
$582K Buy
54,574
+8,530
+19% +$91K ﹤0.01% 3436
2018
Q1
$398K Sell
46,044
-1,215
-3% -$10.5K ﹤0.01% 3600
2017
Q4
$447K Sell
47,259
-153
-0.3% -$1.45K ﹤0.01% 3531
2017
Q3
$372K Sell
47,412
-19,183
-29% -$151K ﹤0.01% 3647
2017
Q2
$572K Buy
66,595
+1,378
+2% +$11.8K ﹤0.01% 3274
2017
Q1
$460K Buy
65,217
+39,411
+153% +$278K ﹤0.01% 3329
2016
Q4
$110K Sell
25,806
-4,678
-15% -$19.9K ﹤0.01% 4345
2016
Q3
$152K Buy
30,484
+2,203
+8% +$11K ﹤0.01% 3910
2016
Q2
$100K Buy
28,281
+4,745
+20% +$16.8K ﹤0.01% 4205
2016
Q1
$81K Buy
23,536
+4,251
+22% +$14.6K ﹤0.01% 4368
2015
Q4
$66K Buy
19,285
+4,638
+32% +$15.9K ﹤0.01% 4538
2015
Q3
$76K Buy
14,647
+8,240
+129% +$42.8K ﹤0.01% 4403
2015
Q2
$44K Buy
6,407
+2,060
+47% +$14.1K ﹤0.01% 4858
2015
Q1
$31K Sell
4,347
-2,335
-35% -$16.7K ﹤0.01% 5026
2014
Q4
$50K Buy
+6,682
New +$50K ﹤0.01% 4724